Efectividad y seguridad de los fármacos biológicos y las moléculas pequeñas en la hidradenitis supurativa: experiencia en un centro terciario y propuesta de un algoritmo terapéutico
Miguel Mansilla-Polo , Begoña Escutia-Muñoz , David Hervás-Marín , Blanca de Unamuno-Bustos , Carlos Abril-Pérez , Rafael Botella-Estrada
{"title":"Efectividad y seguridad de los fármacos biológicos y las moléculas pequeñas en la hidradenitis supurativa: experiencia en un centro terciario y propuesta de un algoritmo terapéutico","authors":"Miguel Mansilla-Polo , Begoña Escutia-Muñoz , David Hervás-Marín , Blanca de Unamuno-Bustos , Carlos Abril-Pérez , Rafael Botella-Estrada","doi":"10.1016/j.piel.2024.02.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Hidradenitis suppurativa is an occasionally devastating inflammatory skin disease. Currently, adalimumab is the only approved biological or small molecule medication for its treatment.</p></div><div><h3>Objectives</h3><p>To evaluate the efficacy and safety of biological or small molecule drugs other than adalimumab, with the ultimate goal of proposing a standardized therapeutic algorithm.</p></div><div><h3>Methods</h3><p>A retrospective study was conducted with all biological or small molecule drugs other than adalimumab in a tertiary hospital. Objective and subjective measurements were recorded through an analysis before (prior to the introduction of the medication) vs. after (withdrawal of the medication or end of the study period).</p></div><div><h3>Results</h3><p>Better response rates than adalimumab were found in most of the objective response items (Hurley, IHS4, HSSI, modified Sartorius) and subjective response items (DLQI, pain, itching, sexual relationships, therapeutic satisfaction) with infliximab leading, followed by ustekinumab, brodalumab, and secukinumab.</p></div>","PeriodicalId":20182,"journal":{"name":"Piel","volume":"39 6","pages":"Pages 317-330"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Piel","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213925124000972","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Hidradenitis suppurativa is an occasionally devastating inflammatory skin disease. Currently, adalimumab is the only approved biological or small molecule medication for its treatment.
Objectives
To evaluate the efficacy and safety of biological or small molecule drugs other than adalimumab, with the ultimate goal of proposing a standardized therapeutic algorithm.
Methods
A retrospective study was conducted with all biological or small molecule drugs other than adalimumab in a tertiary hospital. Objective and subjective measurements were recorded through an analysis before (prior to the introduction of the medication) vs. after (withdrawal of the medication or end of the study period).
Results
Better response rates than adalimumab were found in most of the objective response items (Hurley, IHS4, HSSI, modified Sartorius) and subjective response items (DLQI, pain, itching, sexual relationships, therapeutic satisfaction) with infliximab leading, followed by ustekinumab, brodalumab, and secukinumab.
期刊介绍：
La mejor revista para incrementar eficazmente sus habilidades diagnósticas y clínicas en dermatología, por la alta calidad de sus imágenes e iconografías, por el prestigio de sus colaboradores y por la actualidad de sus temas. Una publicación de máxima utilidad práctica para Especialistas y Profesionales de Atención Primaria.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
